DFTXDefinium Therapeutics, Inc.

Healthcare
$36.91+308% 1Y

The financials

Definium Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Definium Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$75M−$41Mn/a
Net income−$159M−$43Mn/a
Diluted EPS−$1.44−$0.50n/a
On our screens:Stocks with no debtMost shorted stocks

Biotechnology

Ranks #88 of 196 by RyuScore

Compare peers
LGND+2.2%
Ligand Pharmaceuticals Incorporated
BLTE+1.3%
Belite Bio, Inc
CGON+0.93%
CG Oncology, Inc.
LEGN-0.43%
Legend Biotech Corporation
TVTX+0.14%
Travere Therapeutics, Inc.
XENE+0.75%
Xenon Pharmaceuticals Inc.